Mike Hennessy Jr.

Each step of development and manufacturing is becoming more interconnected, and BioPharm's September/October issue highlights the strategies, tools, and innovations shaping the future of the field.

Biopharma’s future depends on seamless integration of technology, expertise, and strategy.

Science is propelling advances and operational shifts in the bio/pharmaceutical industry.

The bio/pharma industry is evolving with intention, intelligence, and a growing sense of shared purpose.

Over the course of the next five years, the bio/pharma industry is expected to see the patents of multiple blockbuster drugs expire, impacting some key industry players.

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

If the conditions prove optimal, 2025 could be a prosperous year for bio/pharma business deals.

The 340B program is under greater scrutiny with more transparency for drug access being demanded by industry.

How the Republican and Democrat presidential candidates might appeal to voters on this topic is starting to be seen.

A coordinated and international response is needed to help control the latest mpox outbreak in Africa.

Will Sanofi’s plan to recruit the younger generation through its participation in the upcoming 2024 Olympic and Paralympic Games, being held in Paris, pay off?

Improved efficiencies and reduced costs are clear advantages of automating drug manufacturing processes.

Technological advances are helping advance biologics development and manufacturing and reduce bottlenecks.

Experts believe it is likely cancer cells are more common in the body than previously thought, but typically caught early and removed in the body’s cancer-immune cycle. When the system is in good working order (and protecting us), dead cancer cells release neoantigens.

While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.

Given its positioning at each new year’s commencement, the J.P. Morgan Healthcare conference helps establish the tone with which the pharmaceutical industry is viewed.

GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.

Pharmaceuticals are entering a transition into a far more complex era of patient therapies, and patient segmentation.

Industry investments indicate increasing trust in the newest modalities, including mRNA approaches.

It has been a long wait, but for Alzheimer’s at least, this is the beginning of renewed hope.

Pharma's ability to continually reinvent itself will be critical in growing future business operations.

A proposed database includes key information about critical drugs, such as the country of origin and quantity, so supply chain weaknesses can be identified.

The debate surrounding drug pricing changes rages on.

COVID-19 has raised the specter of pandemic planning and the question of what can be done now to prevent future disaster.

The engine that drives pharmaceuticals forward, its workforce, is now very low on fuel.

Direct-to-consumer drug advertising has developed as a cottage industry which has been used to increase prescriptions immensely.

That wave beginning to crash over PhRMA’s gunwales may well emanate from a startup mindset, rather than Big Pharma or government policy pundits.

The restraint to not target solely the major disease groups has provided good proportion and balance for our industry.

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.